Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors

被引:42
作者
De Vreese, Rob [1 ]
D'hooghe, Matthias [1 ]
机构
[1] Univ Ghent, Fac Biosci Engn, SynBioC Res Grp, Dept Sustainable Organ Chem & Technol, Coupure Links 653, B-9000 Ghent, Belgium
关键词
Histone deacetylase inhibitor; Benzohydroxamic acid; HDAC6; HDAC8; ACTIVITY IN-VITRO; HYDROXAMIC ACIDS; SELECTIVE INHIBITORS; ANTITUMOR-ACTIVITY; HDAC INHIBITOR; POTENT; DISCOVERY; DESIGN; AR-42; CHEMISTRY;
D O I
10.1016/j.ejmech.2017.04.013
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This paper provides an overview of the synthesis and biological activity of the most representative benzohydroxamic acid-based histone deacetylase inhibitors published to date. Benzohydroxamic acids comprise an important class of HDAC inhibitors, and recently several of these structures have been evaluated in clinical trials for the treatment of a variety of cancers. In this overview, benzohydroxamic acids were divided in four different classes based on their reported selectivity towards zinc-dependent HDACs: a first and major class consists of HDAC6 selective inhibitors, a second class deals with pan-HDAC inhibitors, a third class comprises HDAC8 selective inhibitors and a fourth, minor class includes dual HDAC6/8 selective inhibitors. Through this approach, structure-activity relationships were identified for each class, which could help future researchers in the design and development of novel benzohydroxamic acid-based HDAC inhibitors. (C) 2017 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:174 / 195
页数:22
相关论文
共 66 条
[1]   Epigenetic protein families: a new frontier for drug discovery [J].
Arrowsmith, Cheryl H. ;
Bountra, Chas ;
Fish, Paul V. ;
Lee, Kevin ;
Schapira, Matthieu .
NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (05) :384-400
[2]   A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas [J].
Balasubramanian, S. ;
Ramos, J. ;
Luo, W. ;
Sirisawad, M. ;
Verner, E. ;
Buggy, J. J. .
LEUKEMIA, 2008, 22 (05) :1026-1034
[3]   Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes [J].
Bantscheff, Marcus ;
Hopf, Carsten ;
Savitski, Mikhail M. ;
Dittmann, Antje ;
Grandi, Paola ;
Michon, Anne-Marie ;
Schlegl, Judith ;
Abraham, Yann ;
Becher, Isabelle ;
Bergamini, Giovanna ;
Boesche, Markus ;
Delling, Manja ;
Duempelfeld, Birgit ;
Eberhard, Dirk ;
Huthmacher, Carola ;
Mathieson, Toby ;
Poeckel, Daniel ;
Reader, Valerie ;
Strunk, Katja ;
Sweetman, Gavain ;
Kruse, Ulrich ;
Neubauer, Gitte ;
Ramsden, Nigel G. ;
Drewes, Gerard .
NATURE BIOTECHNOLOGY, 2011, 29 (03) :255-U124
[4]   Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth [J].
Bergman, Joel A. ;
Woan, Karrune ;
Perez-Villarroel, Patricio ;
Villagra, Alejandro ;
Sotomayor, Eduardo M. ;
Kozikowski, Alan P. .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (22) :9891-9899
[5]  
Bertolini G., 1997, Patent No. [US6034096, 6034096]
[6]   Potent Histone Deacetylase Inhibitors Derived from 4-(Aminomethyl)-N-hydroxybenzamide with High Selectivity for the HDAC6 Isoform [J].
Blackburn, Christopher ;
Barrett, Cynthia ;
Chin, Janice ;
Garcia, Kris ;
Gigstad, Kenneth ;
Gould, Alexandra ;
Gutierrez, Juan ;
Harrison, Sean ;
Hoar, Kara ;
Lynch, Chrissie ;
Rowland, R. Scott ;
Tsu, Chris ;
Ringeling, John ;
Xu, He .
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (18) :7201-7211
[7]   Anticancer activities of histone deacetylase inhibitors [J].
Bolden, Jessica E. ;
Peart, Melissa J. ;
Johnstone, Ricky W. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :769-784
[8]  
Breslow R., 1995, Patent No. [WO9531977, 9531977]
[9]  
Breslow R., 2015, Patent No. [WO2015100363, 2015100363]
[10]  
Breslow R., 2013, Patent No. [WO2013052110, 2013052110]